Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

neoantigen-based therapeutic cancer vaccine GRT-C903

A cancer priming vaccine consisting of tumor-specific shared neoantigens, which are immunogenic and unique across a subset of patients, with potential immunostimulating and antineoplastic activities. Upon administration of neoantigen-based therapeutic cancer vaccine GRT-C903, followed by the boosting vaccine GRT-R904, the peptides stimulate the host immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against the shared neoantigens expressed on tumor cells, which results in tumor cell lysis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:priming cancer vaccine GRT-C903
priming vaccine GRT-C903
shared neoantigen cancer vaccine prime GRT-C903
shared neoantigen priming cancer vaccine GRT-C903
Code name:GRT C903
GRT-C903
GRTC903
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search